Increased expression of matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 is correlated with poor prognostic variables in patients with thymic epithelial tumors
Open Access
- 22 October 2003
- Vol. 98 (9) , 1811-1821
- https://doi.org/10.1002/cncr.11725
Abstract
BACKGROUND: A distinction between noninvasive, invasive, and metastatic thymoma on the basis of the cytologic features is difficult. The current study investigated whether the expression of MMP and TIMP was correlated with tumor invasiveness and prognosis in patients with thymoma.METHODS: Tumor tissue samples were obtained from 42 patients with thymic epithelial tumors between 1974 and 2001 at Tokushima University Hospital. Three‐micrometer‐thick, formalin‐fixed, paraffin‐embedded tissue sections were immunostained using specific antibodies against MMP‐2, MMP‐9, TIMP‐1, and TIMP‐2.RESULTS: MMP‐2 expression was detected in 30 tumors (71%), and TIMP‐2 expression was detected in 31 tumors (74%). MMP‐9 expression was detected in 22 of 36 tumors (61%), and TIMP‐1 expression was detected in only 7 tumors (19%). MMP‐2 and TIMP‐2 expression levels were very low (10% and 0%, respectively) in noninvasive tumors but were very high (91% and 97%, respectively) in invasive tumors. In thymic epithelial tumors, the more progressive the clinical stage of tumor, the higher the strongly positive rate of MMP‐2 and TIMP‐2 expression. There was no correlation between positivity for MMP‐9 and stage. Twenty‐five percent of Type AB thymomas and 50% of Type B1 thymomas expressed MMP‐2 and TIMP‐2. Most of Type A, Type B2, Type B3, and Type C thymomas expressed MMP‐2 and TIMP‐2. There were significant differences in disease‐free survival at 5 years between patients without and with MMP‐2 expression (91% vs. 55%, respectively) and patients without and with TIMP‐2 expression (100% vs. 53%, respectively).CONCLUSIONS: MMP‐2 and TIMP‐2 are key enzymes for invasiveness of thymic epithelial tumors. The expression of these proteins can predict a poor outcome in patients with thymoma. Cancer 2003. © 2003 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancerInternational Journal of Cancer, 2002
- New WHO histologic classification predicts prognosis of thymic epithelial tumorsCancer, 2002
- The World Health Organization histologic classification system reflects the oncologic behavior of thymomaCancer, 2002
- Expression of Matrix Metalloproteinases in Invasive Pulmonary Adenocarcinoma with Bronchioloalveolar Component and Atypical Adenomatous HyperplasiaThe American Journal of Pathology, 2001
- Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinomaInternational Journal of Cancer, 2000
- Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formationNature Genetics, 1997
- Cell surface binding and activation of gelatinase A induced by expression of membrane‐type‐1‐matrix metalloproteinase (MT1‐MMP)FEBS Letters, 1996
- Activation of the precursor of gelatinase A/72 kda type IV collagenase/MMP‐2 in lung carcinomas correlates with the expression of membrane‐type matrix metalloproteinase (MT‐MMP) and with lymph node metastasisInternational Journal of Cancer, 1995
- Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrenceInternational Journal of Cancer, 1994
- Tumor Cell Invasion Inhibited by TIMP-2JNCI Journal of the National Cancer Institute, 1991